
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio Inc has experienced a positive shift in its financial landscape following a settlement in 2020 which increased royalty rates on Jemperli sales from 4-8% to 8-25%, along with a one-time payment of $60 million. The outcome of ongoing litigation with GSK could lead to further financial benefits, enhancing AnaptysBio's strategic positioning and potential for future collaborations, all while maintaining a sustainable cash flow to support clinical-stage programs. Management's confidence in the company's value amidst legal challenges, coupled with the prospect of additional indications and assets in development, positions AnaptysBio favorably for future growth.
Bears say
AnaptysBio Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety concerns and lower-than-expected efficacy from its clinical programs, particularly for rosnilimab, which is critical for its growth strategy. Increased competition in the therapeutic landscape and regulatory challenges could further hinder its market position and financial performance, especially if sales do not meet estimations for key products like rosnilimab and Jemperli. Additionally, ongoing legal issues related to intellectual property could lead to diminished revenue and increased legal costs, creating further uncertainty around AnaptysBio's financial stability.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares